cms.bioaccessla.com

Tag: nuclear medicine

  • Radiopharmaceutical Trials In Latin America: Designing Logistics Around Half-Life, Handoffs, And Site Readiness

    Radiopharmaceutical Trials in Latin America: Designing Logistics Around Half-Life, Handoffs, and Site Readiness

    Radiopharmaceutical and radioligand therapies are expanding rapidly, and many sponsors are now looking to Latin America for faster startup, experienced investigators, and access to oncology patient populations. But radiopharma is unforgiving: the physics of radioactive decay turns logistics into a core part of trial design.

    This article focuses on an external knowledge gap we often see in early-stage planning: teams design protocols as if supply behaves like conventional biologics. In radiopharma, half-life, handoffs, and site readiness should be treated as first-order design constraints—especially when operating across borders.

    1) Start with the supply chain reality: isotope generation is often the bottleneck

    A common misconception is that the primary constraint in radiotherapeutics is clinical site availability. In reality, the historically limiting step is often radioisotope generation. Many isotopes rely on specialized production routes and third-party suppliers, and the manufacturing ecosystem is still evolving.

    Planning implication for Latin America: before selecting countries and sites, lock down a realistic isotope supply and production model, including contingency plans for supplier outages and regulatory delays in cross-border transport.

    2) Choose a manufacturing model that matches isotope half-life

    Different isotopes drive different logistics architectures:

    • Longer-lived isotopes (e.g., Lu-177, Ac-225): may support more centralized radiolabeling and batch release models.
    • Shorter-lived isotopes (e.g., Pb-212 ~10.6 hours): push you toward decentralized generation and local radiolabeling close to the patient.

    In Latin America, this choice should also account for: (1) availability of qualified nuclear medicine infrastructure, (2) cross-border shipping routes, and (3) the maturity of local partners (CDMOs, radiopharmacies, and specialized couriers).

    3) Minimize handoffs: every transfer adds time, risk, and decay

    Radiopharma supply chains can involve multiple players exchanging radioactive intermediates or final products before patient administration. Each handoff introduces:

    • Time loss (and therefore activity loss due to decay)
    • Quality risk (chain-of-custody, temperature and shielding controls, documentation)
    • Regulatory friction (hazmat paperwork, customs timing, transport authorizations)

    Design rule: whenever feasible, reduce the number of handoffs by using more integrated partners or regional hub-and-spoke models that shorten shipping legs and standardize handling.

    4) Make “site readiness” a trial endpoint for operations

    Hospitals and treatment centers play a critical role in final handling, storage, and administration. For radiopharma studies, site readiness is not a checkbox—it’s an operational capability. A practical readiness assessment should include:

    • Receiving procedures: trained staff, radiation safety workflows, and documentation discipline.
    • Storage and shielding: compliant storage conditions, monitoring, and access controls.
    • Administration capability: dosing accuracy, decay-aware scheduling, and incident response plans.
    • Waste management: procedures for radioactive waste and contaminated materials.

    In multi-site Latin America trials, variability in readiness is common. Sponsors should plan to standardize training, templates, and QA checks, and to run an early “dry run” shipment where possible.

    5) Logistics is not an afterthought—write it into the protocol

    Many protocols focus heavily on clinical endpoints and adverse event reporting but leave logistics to operational teams late in the process. A stronger approach is to embed decay-aware operational constraints into the protocol and trial execution plan, such as:

    • Scheduling windows for dosing relative to manufacturing time and transport time.
    • Backup visit procedures if shipments are delayed (including re-dosing rules where appropriate).
    • Defined responsibilities across isotope suppliers, CDMOs, couriers, and sites.

    This reduces protocol deviations and avoids the “logistics-driven” screen failures that can quietly erode trial power.

    6) A practical Latin America framework: regional hubs + local radiolabeling where needed

    One pragmatic way to manage Latin America complexity is a regional hub-and-spoke approach:

    • Hub(s): centralized or regional sites with strong infrastructure for radiolabeling and dose formulation.
    • Spokes: patient-facing treatment sites within predictable transport time windows.

    For very short half-life products, the hub may need to be in-country, or you may need local generators and radiolabeling capability. For longer half-life products, regional hubs can reduce redundancy and still meet dosing schedules.

    FAQ

    What is the single biggest logistics factor in radiopharmaceutical trials?

    Half-life. It drives manufacturing model, transport timing, number of handoffs, and site scheduling constraints.

    Can radiopharmaceutical trials be run across multiple Latin America countries?

    Yes, but the supply chain must be designed explicitly for cross-border transport, regulatory requirements for radioactive materials, and realistic customs timelines.

    Should sponsors build in-house radiolabeling capabilities?

    It depends on scale, isotope type, and strategic priorities. Many sponsors partner with CDMOs and specialized providers to avoid costly infrastructure investments while gaining expertise and established safety systems.

    Bottom line: radiopharmaceutical trials succeed when operations are designed around physics. In Latin America, sponsors who align isotope choice, manufacturing model, handoffs, and site readiness can unlock the region’s speed advantages without compromising safety or data integrity.

  • Radiopharmaceutical Trials In Latin America: A Logistics Readiness Framework For Sponsors

    Radiopharmaceutical Trials in Latin America: A Logistics Readiness Framework for Sponsors

    Radiopharmaceutical and theranostics programs have accelerated globally, but their clinical execution has a unique constraint: you are not only running a trial — you are running a time-sensitive supply chain. In Latin America, that supply chain can be a competitive advantage when it is planned well, and a critical risk when it is treated as an afterthought.

    This article offers a practical logistics readiness framework for sponsors planning radiopharmaceutical clinical trials in Latin America. The goal is to help clinical and operational leaders identify failure modes early and design a deployment plan that matches the physics, not just the protocol.

    Why radiopharmaceutical logistics is different

    Radiopharmaceutical trials have “hard” operational constraints: isotope half-life, radiation safety controls, qualified hot lab capacity, imaging standardization, and tightly coordinated shipment windows. In addition, sponsors may need to coordinate with multiple stakeholders — manufacturer, radiopharmacy, courier, customs brokers, hospital nuclear medicine teams, and regulators — where each handoff introduces risk.

    Because of these constraints, a strong sponsor question is: Can we execute the chain reliably, repeatedly, and compliantly for every subject?

    A logistics readiness framework (4 pillars)

    Use the following four pillars to assess readiness before site activation.

    Pillar 1: Isotope supply and contingency planning

    • Primary supply route: Define the manufacturing source, batch release timing, and shipment windows that match enrollment cadence.
    • Secondary route: Identify a backup route for disruptions (transport restrictions, manufacturing delays, flight changes).
    • Buffer strategy: For short half-life isotopes, “buffer” often means operational flexibility (multiple shipment windows) rather than inventory.

    Pillar 2: Regulatory and permit architecture

    • Import permits and documentation: Confirm what must be approved before the first shipment, and what can be handled per-shipment.
    • Labeling and chain-of-custody: Ensure labels, documentation, and custody logs satisfy both radiation safety and clinical trial requirements.
    • Waste and radiation safety: Map disposal pathways and responsibilities with each site to avoid last-minute operational blocks.

    Pillar 3: Site infrastructure and workflow maturity

    • Hot lab capability: Validate equipment, personnel qualification, and SOPs for receipt, preparation, and administration.
    • Scheduling discipline: Radiopharmaceutical administration is scheduling-sensitive. Sites need reliable slot control and patient preparedness workflows.
    • Adverse event readiness: Ensure emergency procedures and escalation pathways are documented and rehearsed.

    Pillar 4: Imaging, dosimetry, and data standardization

    • Imaging protocol consistency: Standardize acquisition parameters and timing relative to administration.
    • Calibration and QA: Establish calibration schedules and quality checks to reduce inter-site variability.
    • Data transfer and review: Define secure transfer pathways, central reads (if used), and turnaround expectations.

    Common failure modes — and how to prevent them

    • Enrollment outpaces supply planning: Align recruitment targets to realistic shipment cadence and site throughput.
    • Customs and documentation surprises: Create country-specific shipment playbooks and run a “first shipment rehearsal.”
    • Inconsistent imaging: Use standardized checklists and training, and consider centralized QA early.
    • Site capability overestimation: Validate the workflow in practice, not only on paper. A site can be clinically excellent and still operationally unready for radiopharmaceutical constraints.

    FAQ

    1) What should we assess first when choosing Latin American countries for radiopharmaceutical trials?
    Start with isotope availability routes, hot lab capacity, and the country’s ability to support compliant import and radiation safety workflows. If those are weak, other advantages will not compensate.

    2) Are logistics risks higher in Latin America than in the U.S. or EU?
    They are different. Risks often relate to cross-border shipment orchestration and variability in infrastructure by site. With the right planning and experienced operators, sponsors can build reliable execution pathways.

    3) How do we prevent schedule failures due to isotope half-life constraints?
    Design your operational plan around the isotope clock: confirmed shipment windows, controlled scheduling, backup routes, and rapid communication workflows across all parties.

    Bottom line: Radiopharmaceutical clinical trials reward operational maturity. Sponsors that treat logistics as a core part of trial design — not a downstream task — can unlock faster, more reliable execution across Latin America.